Press Releases GRAIL, Inc.

Equities

GRAL

US3847471014

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
97.50 ^USD	+1.68%		-2.89%	+13.92%

Feb. 04	Hims & Hers Health, Inc. Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care	CI
Feb. 04	Hims & Hers Offers Multi-Cancer Blood Screening Through New Partnership	MT

Press Releases

Feb. 16	GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results	PR
Jan. 29	GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test	PR
Jan. 12	GRAIL : 44th Annual J.P. Morgan Healthcare Conference (January 12, 2026)	PU
Dec. 15	GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference	PR
Dec. 10	GRAIL : Biopsy-Free Detection of Residual Urothelial Carcinoma via Cell-Free DNA Methylation in Pre-Operative Urine and Plasma View Presentation	PU
Dec. 09	GRAIL : Non-Invasive Urinary Detection of Upper Tract Urothelial Carcinoma via Methylation Patterns in Cell-Free DNA View Presentation	PU
Dec. 01	GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
Nov. 18	GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference	PR
Nov. 13	GRAIL : 2025 Analyst Day Presentation (November 13, 2025)	PU
Nov. 12	GRAIL Reports Third Quarter 2025 Financial Results	PR
Nov. 11	GRAIL : Mapping the Evidence on Interrelationships Between Cancer Stage, Financial Toxicity (FT), and Health-Related Quality of Life (HRQoL) View Presentation	PU
Nov. 10	Mental and Behavioral Health Disorders (MBHD) Among Patients with Metastatic and Non-Metastatic Cancer: A Claims-Based Analysis View Presentation	PU
Nov. 06	The NHS-Galleri trial: What to expect in 2026 from the world’s first randomized controlled trial of a Multi-Cancer Early Detection test, Galleri®	PU
Nov. 04	GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference	PR
Nov. 03	GRAIL : Cancer signal origin (CSO) prediction in cancer of unknown primary (CUP) syndrome (CRONUS) using circulating tumor DNA (ctDNA) View Presentation	PU
25-10-29	GRAIL to Announce Third Quarter 2025 Financial Results	PR
25-10-22	REFLECTION: Real-World Evidence Study of Multi-Cancer Early Detection (MCED) Among Veterans in the Veterans Affairs Healthcare System - Presentation View Presentation	PU
25-10-21	NHS-Galleri Trial: Approaches to Retain a Diverse Participant Cohort Across Multiple Trial Appointments View Presentation	PU
25-10-21	GRAIL : Molecular Cancer Signal Localization in Multi-Cancer Early Detection (MCED) Testing Minimizes Radiation and Imaging Burden Compared to Whole-Body Imaging Approaches View Presentation	PU
25-10-21	GRAIL : PATHFINDER 2 Study (Grail Pathfinder2 Fact Sheet)	PU
25-10-20	GRAIL : PATHFINDER 2 Study Results Presented at ESMO 2025 (October 20, 2025)	PU
25-10-20	GRAIL : and University of Oxford Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)	PU
25-10-20	GRAIL, Inc. Announces $325.0 Million Private Placement Financing	PR
25-10-20	GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)	PR
25-10-18	GRAIL : Understanding the Galleri Test (GRAIL Galleri Fact Sheet)	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases GRAIL, Inc.

Equities

GRAL

US3847471014

Biotechnology & Medical Research

Press Releases

Filters